What is she best known for?
The fields of study she is best known for:
- Enzyme
- Gene
- Organic chemistry
Her primary scientific interests are in Drug discovery, Stereochemistry, Acetylcholinesterase, Binding site and Biochemistry.
Her work carried out in the field of Drug discovery brings together such families of science as Multi target, Computational biology and Drug.
Her Stereochemistry research incorporates elements of Molecule, Structure–activity relationship, Chemical synthesis, Peptide and Amyloid.
Her Acetylcholinesterase research incorporates themes from Alzheimer's disease, Neurotoxicity, Acridine and Enzyme inhibitor.
Her Binding site study combines topics in areas such as Plasma protein binding, Bioavailability and Ligand.
Her studies deal with areas such as QT interval, Ligand and Molecular dynamics as well as Bioinformatics.
Her most cited work include:
- Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases (749 citations)
- Role of Molecular Dynamics and Related Methods in Drug Discovery. (337 citations)
- Role of Molecular Dynamics and Related Methods in Drug Discovery. (337 citations)
What are the main themes of her work throughout her whole career to date?
Andrea Cavalli mainly investigates Drug discovery, Stereochemistry, Biochemistry, Molecular dynamics and Pharmacology.
Her biological study spans a wide range of topics, including Virtual screening, Docking, In silico and Computational biology.
Her study in Stereochemistry is interdisciplinary in nature, drawing from both Acetylcholinesterase, Active site, Lead compound, Structure–activity relationship and Chemical synthesis.
Her Acetylcholinesterase course of study focuses on Enzyme inhibitor and Molecular model.
In her research, Plasma protein binding and Metadynamics is intimately related to Ligand, which falls under the overarching field of Molecular dynamics.
Her Pharmacology research is multidisciplinary, incorporating elements of Memantine, Galantamine and Disease.
She most often published in these fields:
- Drug discovery (40.00%)
- Stereochemistry (28.86%)
- Biochemistry (23.80%)
What were the highlights of her more recent work (between 2018-2021)?
- Drug discovery (40.00%)
- Molecular dynamics (26.33%)
- Pharmacology (24.30%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Drug discovery, Molecular dynamics, Pharmacology, Biophysics and Homologous recombination.
Her work deals with themes such as Surface plasmon resonance, Metadynamics and Rational design, which intersect with Drug discovery.
Her study looks at the relationship between Molecular dynamics and fields such as Extracellular, as well as how they intersect with chemical problems.
Her Pharmacology research includes elements of In vitro, Fluoxetine and Sertraline.
Her Biophysics study incorporates themes from Redox, Tissue damage, HMGB1 and Oxidation state.
She interconnects Allosteric regulation, Small molecule and Binding site in the investigation of issues within Computational biology.
Between 2018 and 2021, her most popular works were:
- Kinetics of Drug Binding and Residence Time (23 citations)
- Kinetics of Drug Binding and Residence Time (23 citations)
- Predicting Residence Time and Drug Unbinding Pathway through Scaled Molecular Dynamics. (20 citations)
In her most recent research, the most cited papers focused on:
- Enzyme
- Gene
- Organic chemistry
Drug discovery, Molecular dynamics, Metadynamics, Synthetic lethality and Pancreatic cancer are her primary areas of study.
Her Drug discovery study combines topics from a wide range of disciplines, such as Molecular simulation, Drug target and Biochemical engineering.
The study incorporates disciplines such as Chemical physics, Biological system and Dimensionality reduction in addition to Molecular dynamics.
The Metadynamics study combines topics in areas such as Statistical physics, Markov chain and Complement.
The concepts of her Synthetic lethality study are interwoven with issues in Cancer research, Olaparib, RAD51, Homologous recombination and Ovarian cancer.
Her Pancreatic cancer research is multidisciplinary, relying on both Synthetic Lethal Mutations, PARP inhibitor, DNA and Poly Polymerase Inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
